Nice charts, thanks for posting. Starting with the 2nd chart, the double bottom or "W" formation is very apparent. "They" may try one more take-down, judging from the crazed posting on the other site, and maybe that gap will fill (so back down briefly to 2.38ish) but I hope that we are finally going to get the news that will take us back up to a more reasonable valuation.

Hard to believe that a stock with 3 drugs in clinical trials, in 3 different areas of medicine, can be so unloved and undervalued.